Artelo Biosciences, Inc.
ARTL
$7.20
$0.11021.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -25.52% | 53.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.59% | 219.00% | |||
| Operating Income | 37.59% | -219.00% | |||
| Income Before Tax | 37.22% | -233.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.22% | -233.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.22% | -233.75% | |||
| EBIT | 37.59% | -219.00% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 37.75% | -231.17% | |||
| Normalized Basic EPS | 38.31% | -216.51% | |||
| EPS Diluted | 37.75% | -231.17% | |||
| Normalized Diluted EPS | 38.31% | -216.51% | |||
| Average Basic Shares Outstanding | 0.86% | 0.77% | |||
| Average Diluted Shares Outstanding | 0.86% | 0.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||